HomeCompareSPHRF vs BTI

SPHRF vs BTI: Dividend Comparison 2026

SPHRF yields 606.06% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280371.13M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — SPHRF vs BTI

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, SPHRF beats the other by $179,917,782,065.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + BTI for your $10,000?

SPHRF: 50%BTI: 50%
100% BTI50/50100% SPHRF
Portfolio after 10yr
$140185.60M
Annual income
$105,833,992,237.12/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
BTI buys
0
No recent congressional trades found for SPHRF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFBTI
Forward yield606.06%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$280371.17M$37.7K
Annual income after 10y$211,667,981,687.60$2,786.64
Total dividends collected$274648.71M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SPHRF vs BTI ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$71,306$60,606.06$11,299$598.92+$60.0KSPHRF
2$480,183$403,885.93$12,794$703.91+$467.4KSPHRF
3$3,055,680$2,541,883.57$14,518$829.07+$3.04MSPHRF
4$18,386,820$15,117,242.14$16,513$978.64+$18.37MSPHRF
5$104,687,331$85,013,433.96$18,827$1,157.84+$104.67MSPHRF
6$564,382,839$452,367,394.46$21,518$1,373.12+$564.36MSPHRF
7$2,883,114,581$2,279,224,943.60$24,657$1,632.46+$2883.09MSPHRF
8$13,966,501,456$10,881,568,854.67$28,329$1,945.74+$13966.47MSPHRF
9$64,208,586,900$49,264,430,341.75$32,637$2,325.33+$64208.55MSPHRF
10$280,371,169,670$211,667,981,687.60$37,708$2,786.64+$280371.13MSPHRF

SPHRF vs BTI: Complete Analysis 2026

SPHRFStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SPHRF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.